Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments
Key facts
- Where
- Antibes Cedex, Cannes Cedex, Clermont-Ferrand, CRETEIL, La Roche-sur-Yon, Marseille, Nice, Paris, and Paris Cedex 10, FranceSee the 9 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT07501507, who can take part
Where in France
- Centre Hospitalier D'Antibes Juan Les PinsAntibes Cedex, FranceTaking people
- Centre Hospitalier De Cannes Simone VeilCannes Cedex, FranceTaking people
- Centre Hospitalier Universitaire Gabriel MontpiedClermont-Ferrand, FranceTaking people
- HOPITLA HENRI MONDORCRETEIL, FranceTaking people
- Centre Hospitalier Départemental VendéeLa Roche-sur-Yon, FranceTaking people
- Hôpital Saint JosephMarseille, FranceTaking people
- Centre Hospitalier Universitaire de NiceNice, FranceTaking people
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 10, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Trial code
- NCT07501507EU 2022-502362-24-00
- Record updated
- 24 September 2026
- Original description
Randomized study comparing the structural efficacy of methotrexate versus placebo in digital osteoarthritisRead full original descriptionShow less
Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments: A Randomised, Double-blind, Placebo-controlled Trial
Randomized study comparing the structural efficacy of methotrexate versus placebo in digital osteoarthritis
Inclusion: Digital osteoarthritis (IPD and IPP) according to ACR criteria (with an X-ray of the hands taken less than 3 months ago, showing at least 3 joints with digital osteoarthritis KL>=2) and symptomatic for more than three months.
Exclusion: Injection of hyaluronic acid within the previous 6 months,; Injection of cortisone derivatives within the previous 3 months,; Use of corticosteroids; Major progressive disease (life-threatening cardiovascular disease, hematopoietic cancers including myeloma, cancers with risk of bone metastases),; Liver failure; Positive hepatitis B serology; Tuberculosis, hepatitis C, HIV positive, or other immunodeficiency syndromes; Uncontrolled infections; Having a bilirubin level > 5 mg/dl (85.5 µmol/l); Severe renal failure (creatinine clearance less than 50 ml/min); Pregnant or breastfeeding women (a urine pregnancy test will be performed on women of childbearing age),; Presence of psoriasis,; Inflammatory rheumatism,; Microcrystalline arthropathy,; Joint prosthesis in one of the joints of the hand,; Planned placement of a joint prosthesis in the hand during the study period,; Use of morphine derivatives,; Taking Bactrim,; Taking high doses of aspirin (greater than or equal to 500mg/day),; Contraindications to the use of methotrexate,.